Abstract
Cyclic 3-hydroxymelatonin (C3HOM) is an immediate product of melatonin’s interaction with reactive oxygen species. Its presence has been detected in mice, rats and humans. In the current study, the antioxidant capacity and reducing power of this molecule have been systematically studied. C3HOM is found to be a more potent antioxidant than melatonin or vitamin C in terms of its ability to scavenge the hydroxyl radical (HO.) and to recover oxidized horseradish peroxidase to its ground state. The antioxidative mechanism of C3HOM is similar to that of the classic antioxidant, vitamin C, rather than to its precursor melatonin. C3HOM effectively prevents the oxidative degradation of cytochrome C induced by hydrogen peroxide (H2O2). It is speculated that some antioxidative activities of melatonin may be mediated by its metabolite, C3HOM. C3HOM prevents mitochondrial cytochrome C injury and, thus, it is likely to inhibit cellular apoptosis induced by the release of oxidized cytochrome C from mitochondria.
Keywords: Antioxidant, cyclic-3-hydroxymelatonin, cytochrome C, free radical chemiluminescence, melatonin.
Current Medicinal Chemistry
Title:Cyclic-3-hydroxymelatonin (C3HOM), A Potent Antioxidant, Scavenges Free Radicals and Suppresses Oxidative Reactions
Volume: 21 Issue: 13
Author(s): Dun-Xian Tan, R. Hardeland, L.C. Manchester, A. Galano and R.J. Reiter
Affiliation:
Keywords: Antioxidant, cyclic-3-hydroxymelatonin, cytochrome C, free radical chemiluminescence, melatonin.
Abstract: Cyclic 3-hydroxymelatonin (C3HOM) is an immediate product of melatonin’s interaction with reactive oxygen species. Its presence has been detected in mice, rats and humans. In the current study, the antioxidant capacity and reducing power of this molecule have been systematically studied. C3HOM is found to be a more potent antioxidant than melatonin or vitamin C in terms of its ability to scavenge the hydroxyl radical (HO.) and to recover oxidized horseradish peroxidase to its ground state. The antioxidative mechanism of C3HOM is similar to that of the classic antioxidant, vitamin C, rather than to its precursor melatonin. C3HOM effectively prevents the oxidative degradation of cytochrome C induced by hydrogen peroxide (H2O2). It is speculated that some antioxidative activities of melatonin may be mediated by its metabolite, C3HOM. C3HOM prevents mitochondrial cytochrome C injury and, thus, it is likely to inhibit cellular apoptosis induced by the release of oxidized cytochrome C from mitochondria.
Export Options
About this article
Cite this article as:
Tan Dun-Xian, Hardeland R., Manchester L.C., Galano A. and Reiter R.J., Cyclic-3-hydroxymelatonin (C3HOM), A Potent Antioxidant, Scavenges Free Radicals and Suppresses Oxidative Reactions, Current Medicinal Chemistry 2014; 21 (13) . https://dx.doi.org/10.2174/0929867321666131129113146
DOI https://dx.doi.org/10.2174/0929867321666131129113146 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Regulation of Neural Stem Cells in the Human SVZ by Trophic and Morphogenic Factors
Current Signal Transduction Therapy Tumor Invasion and Oxidative Stress: Biomarkers and Therapeutic Strategies
Current Molecular Medicine Innate Immunity and the Heart
Current Pharmaceutical Design Biology of PPARγ in Cancer: A Critical Review on Existing Lacunae
Current Molecular Medicine Macrolides in Community-Acquired Pneumonia: The Importance of the Non-Antimicrobial Effect
Current Respiratory Medicine Reviews Attenuating Muscle Wasting: Cell and Gene Therapy Approaches
Current Genomics Phytoestrogens and Mitochondrial Biogenesis in Breast Cancer. Influence of Estrogen Receptors Ratio
Current Pharmaceutical Design Endocannabinoid Blockade and the Cardiovascular System
Current Drug Therapy Developing Immunologically Inert Adeno-Associated Virus (AAV) Vectors for Gene Therapy: Possibilities and Limitations
Current Pharmaceutical Biotechnology Unlocking the Molecular Mechanisms of DNA Repair and Platinum Drug Resistance in Cancer Chemotherapy
Current Drug Therapy Biologic Agents in the Treatment of Rheumatoid Arthritis
Current Pharmaceutical Biotechnology Analgesic Prodrugs for Combating their Side-Effects: Rational Approach
Current Drug Delivery The Spleen Tyrosine Kinase (Syk) in Human Disease, Implications for Design of Tyrosine Kinase Inhibitor Based Therapy
Current Pharmaceutical Design Combining Gene Therapy and Radiation Against Cancer
Current Gene Therapy Surfactant Protein A - From Genes to Human Lung Diseases
Current Medicinal Chemistry Subject Index to Volume 4
Current Pharmaceutical Biotechnology Complications Following Stem Cell Therapy in Inflammatory Bowel Disease
Current Stem Cell Research & Therapy Modulatory Factors Responsible for Neoangiogenesis in Young Patients with Long-Standing Diabetes Mellitus Type 1
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) In silico Molecular Interaction Analysis of LTNF Peptide-LT10 with Snake Venom Enzymes
Protein & Peptide Letters Delivering Resveratrol on the Buccal Mucosa Using Mucoadhesive Tablets: A Potential Treatment Strategy for Inflammatory Oral Lesions
Current Drug Delivery